Matchmaking option:
Gwo Xi Stem Cell Applied Technology Co., Ltd.
GWOXI Stem Cell R&D Center was established in 2011 and committed to developing the potential stem cell therapies that satisfy the unmet medical needs and further contribute to the medical field. The production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan by now including GXHPC1, GXNPC1, and GXCPC1, indications of liver cirrhosis, stroke, and osteoarthritis, respectively. In addition, we currently also have a clinical trial, GXIPC1 is going in Vietnam, which is applied for type I diabetes executed in Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG). Four clinical trials are using adipose-derived stem cells (ADSCs) as cell sources, and the administrations are local transplantation instead of intravenous injection, which have great potential for improving outcomes. The safety reports related to clinical trials using stem cells are provided by our testing lab, GTESTing® lab (TAF certification number: 2800), which is with the international standard for laboratory quality system. So far, we have established R&D Center, ATMP lab, and PIC/S GMP stem cell factory for developing and manufacturing advanced cell therapy products. In the future, based on our established research capability, we will actively promote innovative stem cell products from Taiwan to the international market through collaboration with strategic partners of the alliance.
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
Contact Us